Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
POLYMORPHS OF 7-[(3-CHLOR0-6,11-DIHYDRO-6-
METHYLDIBENZO[C,F][1,2]THIAZEPIN-11-YL)AMINO]HEPTANOIC ACID
S,S-DIOXIDE AND METHODS OF MAKING AND USING THE SAME
FIELD OF THE INVENTION
[001] The present invention relates to novel polymorphs of 7-[(3-chloro-6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide.
The invention also provides methods of using one or more 7-[(3-chloro-6,11-
dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide
polymorphs
in an oral dosage pharmaceutical composition and related methods of treatment.
BACKGROUND OF THE INVENTION
[002] 7- [(3-chloro-6,11-dihydro-6-methyldib enzo [c,f] [1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide is a tricyclic compound also known as
tianeptine.
7- [(3 -chloro-6,11-dihydro-6-methyldib enzo [c,f] [1 ,2]thiazepin-11-
yl)amino] heptanoic
acid S,S-dioxide is an antidepressant. The free form of 7-[(3-chloro-6,11-
dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide is
amphoteric and an amorphous sodium salt is known in the art.
[003] Synthesis of the 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide sodium
salt
is disclosed in U.S. Patent No. 3,758,528. The 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide sodium
salt
(i.e., STABLONO) is currently approved in European countries for the treatment
of
one or more depressive disorders. STABLONO (7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide
sodium) has
a short half-life and effective treatment often requires dosing multiple times
each day.
[004] Presently, a pharmaceutical composition of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide sodium
is
generally dosed orally up to three times a day. This frequent oral dosing may
lead to
decreased compliance with the recommended dosing regimen. A controlled release
pharmaceutical composition of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide should
enable better command over the release profile and consequently, a less
demanding
1
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
dosing regimen. A polymorph of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide free
form
may be advantageous in the preparation of a controlled release pharmaceutical
composition comprising 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-
11-yl)amino]heptanoic acid S,S-dioxide.
BRIEF SUMMARY OF THE INVENTION
[005] The present invention relates to novel polymorphs of 7-[(3-chloro-6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide.
These novel polymorphs can exhibit improved properties relative to the
currently
marketed 7- [(3 -chloro-6,11 -dihydro-6-methyldib enzo [c, f] [1,2]thiazepin-
11-
yl)amino]heptanoic acid S,S-dioxide sodium salt. Such improved properties can
include, but are not limited to, crystallinity, purity, and physical
stability. The
invention also provides novel pharmaceutical compositions comprising one or
more
polymorphs of 7- [(3-chloro-6,11 -dihydro-6-methyldib enzo [c, f]
[1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide, methods of making polymorphs of 7-[(3-
chloro-
6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide, and related methods of treatment. For example, 7-[(3-chloro-6,11-
dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form I
or 7-
[(3 -chloro-6,11 -dihydro-6-methyldib enzo [c, f] [1,2]thiazep in-11 -
yl)amino] heptanoic
acid S,S-dioxide Form II provide an alternative in a pharmaceutical
composition to the
currently marketed form, 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide sodium
salt.
[006] 7- [(3-chloro-6 ,11 -dihydro-6-methyldib enzo [c,f] [1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide has the following structure (I):
2
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
=/
N \ /
Si
0
HO N
101
H
CI
0
(I).
[007] The polymorphs of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide can be
used
to provide pharmaceutical compositions for the treatment of conditions known
in the
art, such as one or more depressive disorders, irritable bowel syndrome (IBS),
attention
deficit hyperactivity disorder (ADHD), and asthma.
[008] For a better understanding of the present invention, together with other
and
further embodiments thereof, reference is made to the accompanying drawings
and
detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[009] Figure 1- PXRD diffractogram of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form I
[0010] Figure 2- DSC thermogram of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form I
[0011] Figure 3- TGA thermogram of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form I
[0012] Figure 4- IR spectrum of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form I
3
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
[0013] Figure 5- PXRD diffractogram of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II
[0014] Figure 6- DSC thermogram of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II
[0015] Figure 7- TGA thermogram of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II
[0016] Figure 8- IR spectrum of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II
DETAILED DESCRIPTION OF THE INVENTION
[0017] The present invention relates to novel polymorphs of 7-[(3-chloro-6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide.
The properties of the polymorphs of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide can be
improved relative to one or more known forms of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide, such
as 7-
[(3 -chloro-6,11 -dihydro-6-methyldib enzo [c, f] [1,2]thiazep in-11 -
yl)amino] heptanoic
acid S,S-dioxide sodium (the currently marketed form). Such improved
properties can
include, but are not limited to, crystallinity, purity, and physical
stability. The
invention also includes other forms of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide
including,
but not limited to, co-crystals and amorphous forms. The invention also
provides novel
pharmaceutical compositions comprising these forms, methods of making these
forms,
and related methods of treatment.
[0018] The present invention comprises polymorphs of 7-[(3-chloro-6,11-dihydro-
6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide. 7-
[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide has the following structure (I):
4
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
= /
\ Sel
----0
HO N
101
H
CI
0
(I).
[0019] In a first embodiment, the present invention comprises a polymorph of 7-
[(3 -chloro-6,11-dihydro-6-methyldib enzo [c,f] [1,2]thiazepin-11-
yl)amino]heptanoic
acid S,S-dioxide.
[0020] In a further embodiment, one or more polymorphs of 7-[(3-chloro-6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
can be incorporated into a pharmaceutical composition. In a further
embodiment, one
or more polymorphs of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-
11-yl)amino]heptanoic acid S,S-dioxide can be incorporated into a controlled
release
pharmaceutical composition.
[0021] In another embodiment, a polymorph of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide can be
incorporated into a pharmaceutical composition comprising two or more layers
of said
polymorph such that one layer is substantially released prior to the
substantial release
of another layer in vivo. In another embodiment, a polymorph of 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
can be incorporated into a pharmaceutical composition comprising pellets,
wherein the
pellets have varying extents or compositions of coating so as to enable
release of the 7-
[(3 -chloro-6,11-dihydro-6-methyldib enzo [c,f] [1,2]thiazepin-11-
yl)amino]heptanoic
acid S,S-dioxide over a substantially longer period of time than that of the
currently
available sodium salt (e.g., STABLONO).
[0022] In another embodiment, a polymorph of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide can be
incorporated into an osmotically active pharmaceutical composition suitable
for oral
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
administration. Osmotically active pharmaceutical compositions, osmotic pumps,
osmotic drug delivery, and other osmotic technology suitable for oral
administration
can include, but are not limited to, OROSO Push-Pull and OROSO Tr-layer
pharmaceutical compositions. In another embodiment, a polymorph of 7-[(3-
chloro-
6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid 5,5-
dioxide can be incorporated into an OROSO drug delivery system. Such
controlled
release pharmaceutical compositions comprising a polymorph of 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide,
such as an osmotically active pharmaceutical composition suitable for oral
administration, may lead to a longer lasting therapeutic effect than that of
the 7-[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide sodium salt in the currently marketed form.
[0023] In another embodiment, the present invention comprises 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
Form I. In another embodiment, the present invention comprises 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
Form I, wherein said Form I exhibits a PXRD diffractogram comprising a peak at
about
5.89 degrees 2-theta. In another embodiment, the present invention comprises 7-
[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide Form I, wherein said Form I exhibits a PXRD diffractogram
comprising a
peak at about 7.82 degrees 2-theta. In another embodiment, the present
invention
comprises 7- [(3 -chloro-6,11-dihydro-6-methyldib enzo [c,f] [1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide Form I, wherein said Form I exhibits a
PXRD
diffractogram comprising a peak at about 8.93 degrees 2-theta. In another
embodiment,
the present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
wherein said Form I exhibits a PXRD diffractogram comprising peaks at about
7.82
and about 8.93 degrees 2-theta. In another embodiment, the present invention
comprises 7- [(3 -chloro-6,11-dihydro-6-methyldib enzo [c,f] [1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide Form I, wherein said Form I exhibits a
PXRD
diffractogram comprising peaks at about 5.89 and about 7.82 degrees 2-theta.
In
another embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-
6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
6
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
wherein said Form I exhibits a PXRD diffractogram comprising peaks at about
12.66
and about 13.32 degrees 2-theta. In another embodiment, the present invention
comprises 7- [(3 -chloro-6,11-dihydro-6-methyldib enzo [c,f] [1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide Form I, wherein said Form I exhibits a
PXRD
diffractogram comprising peaks at about 5.89, about 7.82, and about 8.93
degrees 2-
theta. In another embodiment, the present invention comprises 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
Form I, wherein said Form I exhibits a PXRD diffractogram comprising peaks at
about
5.89, about 12.66, about 13.32, and about 17.64 degrees 2-theta. In another
embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
wherein said Form I exhibits a PXRD diffractogram comprising peaks at about
7.82,
about 8.93, about 12.66, about 13.32, and about 14.72 degrees 2-theta. In
another
embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
wherein said Form I exhibits a PXRD diffractogram comprising peaks at about
5.89,
about 7.82, about 8.93, and about 13.32 degrees 2-theta. In another
embodiment, the
present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
wherein said Form I exhibits a PXRD diffractogram comprising peaks at about
14.72,
about 16.26, about 17.64, and about 19.50 degrees 2-theta. In another
embodiment, the
present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
wherein said Form I exhibits a PXRD diffractogram comprising peaks at about
5.89,
about 7.82, about 8.93, about 16.26, and about 19.50 degrees 2-theta. In
another
embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
wherein said Form I exhibits a PXRD diffractogram comprising peaks at about
5.89,
about 7.82, about 8.93, about 12.66, about 13.32, and about 14.72 degrees 2-
theta. In
another embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-
6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
wherein said Form I exhibits a PXRD diffractogram comprising peaks at about
5.89,
about 7.82, about 8.93, about 12.66, about 13.32, about 14.72, about 16.26,
about
7
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
17.64, about 19.50, about 21.56, about 22.58, and about 25.19 degrees 2-theta.
In
another embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-
6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
wherein said Form I exhibits a PXRD diffractogram substantially similar to
Figure 1.
In another embodiment, the present invention comprises 7-[(3-chloro-6,11-
dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I,
wherein said Form I exhibits a DSC thermogram comprising an endothermic
transition
at about 139 degrees C. In another embodiment, the present invention comprises
7-[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide Form I, wherein said Form I exhibits a DSC thermogram
substantially
similar to Figure 2. In another embodiment, the present invention comprises 7-
[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide Form I, wherein said Form I exhibits a TGA thermogram
substantially
similar to Figure 3. In another embodiment, the present invention comprises 7-
[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide Form I, wherein said Form I exhibits an IR spectrum substantially
similar
to Figure 4. In another embodiment, 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form I
is
incorporated into a controlled release pharmaceutical composition.
[0024] In another embodiment, the present invention comprises 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
Form II. In another embodiment, the present invention comprises 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
Form II, wherein said Form II exhibits a PXRD diffractogram comprising a peak
at
about 8.52 degrees 2-theta. In another embodiment, the present invention
comprises 7-
[(3 -chloro-6,11-dihydro-6-methyldib enzo [c, f] [1,2]thiazepin-11-
yl)amino]heptanoic
acid S,S-dioxide Form II, wherein said Form II exhibits a PXRD diffractogram
comprising a peak at about 10.46 degrees 2-theta. In another embodiment, the
present
invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide Form II, wherein said Form II exhibits a
PXRD
diffractogram comprising a peak at about 15.05 degrees 2-theta. In another
embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
8
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
wherein said Form II exhibits a PXRD diffractogram comprising peaks at about
8.52
and about 10.46 degrees 2-theta. In another embodiment, the present invention
comprises 7- [(3 -chloro-6,11-dihydro-6-methyldib enzo [c,f] [1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide Form II, wherein said Form II exhibits a
PXRD
diffractogram comprising peaks at about 8.52 and about 17.14 degrees 2-theta.
In
another embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-
6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
wherein said Form II exhibits a PXRD diffractogram comprising peaks at about
10.46
and about 17.14 degrees 2-theta. In another embodiment, the present invention
comprises 7- [(3 -chloro-6,11-dihydro-6-methyldib enzo [c, f] [1,2]thiazepin-
11-
yl)amino]heptanoic acid S,S-dioxide Form II, wherein said Form II exhibits a
PXRD
diffractogram comprising peaks at about 8.52, about 10.46, and about 15.05
degrees 2-
theta. In another embodiment, the present invention comprises 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
Form II, wherein said Form II exhibits a PXRD diffractogram comprising peaks
at
about 15.05, about 17.14, about 18.22, and about 20.99 degrees 2-theta. In
another
embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
wherein said Form II exhibits a PXRD diffractogram comprising peaks at about
8.52,
about 10.46, about 17.14, about 22.68, and about 23.35 degrees 2-theta. In
another
embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
wherein said Form II exhibits a PXRD diffractogram comprising peaks at about
8.52,
about 15.05, about 20.99, and about 21.66 degrees 2-theta. In another
embodiment, the
present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
wherein said Form II exhibits a PXRD diffractogram comprising peaks at about
10.46,
about 17.14, about 18.22, and about 21.66 degrees 2-theta. In another
embodiment, the
present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
wherein said Form II exhibits a PXRD diffractogram comprising peaks at about
8.52,
about 10.46, about 15.05, about 17.14, and about 18.22 degrees 2-theta. In
another
embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-6-
9
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
wherein said Form II exhibits a PXRD diffractogram comprising peaks at about
8.52,
about 10.46, about 15.05, about 17.14, about 18.22, and about 20.99 degrees 2-
theta.
In another embodiment, the present invention comprises 7-[(3-chloro-6,11-
dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
wherein said Form II exhibits a PXRD diffractogram comprising peaks at about
8.52,
about 10.46, about 15.05, about 17.14, about 18.22, about 20.99, about 21.66,
about
22.68, about 23.35, about 23.88, about 24.55, and about 26.71 degrees 2-theta.
In
another embodiment, the present invention comprises 7-[(3-chloro-6,11-dihydro-
6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
wherein said Form II exhibits a PXRD diffractogram substantially similar to
Figure 5.
In another embodiment, the present invention comprises 7-[(3-chloro-6,11-
dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II,
wherein said Form II exhibits a DSC thermogram comprising an endothermic
transition
at about 148 degrees C. In another embodiment, the present invention comprises
7-[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide Form II, wherein said Form II exhibits a DSC thermogram
substantially
similar to Figure 6. In another embodiment, the present invention comprises 7-
[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide Form II, wherein said Form II exhibits a TGA thermogram
substantially
similar to Figure 7. In another embodiment, the present invention comprises 7-
[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide Form II, wherein said Form II exhibits an IR spectrum
substantially similar
to Figure 8. In another embodiment, 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II is
incorporated into a controlled release pharmaceutical composition.
[0025] In another embodiment, the present invention comprises 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
Form I, and methods of making and using the same. In another embodiment, the
present invention comprises 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II, and
methods of making and using the same.
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
[0026] In another embodiment, the present invention provides a method of
making
a polymorph of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide, comprising:
(a) providing 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide sodium salt; and
(b) contacting said 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide sodium salt with an appropriate acid so as to desalify said
sodium salt;
(c) contacting the desalified mixture from step (b) with an appropriate
solvent; and
(d) crystallizing said polymorph of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide.
[0027] In a specific embodiment, a solvent is added to said 7-[(3-chloro-6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
sodium salt prior to said appropriate acid. In another embodiment, step (b) is
completed in the presence of a solvent such that a solution is formed prior to
crystallization of the 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide polymorph. In another embodiment, step (b)
is
completed in the presence of a solvent such that a suspension is formed prior
to
crystallization of the 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide polymorph. In a specific embodiment, said
polymorph of 7- [(3-chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-
11-
yl)amino]heptanoic acid S,S-dioxide is 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I. In
certain embodiments, an appropriate solvent is selected from the group
consisting of:
acetone, ethanol, nitromethane, methanol, acetonitrile, dichloromethane,
water, and
tetrahydrofuran (THF). In another embodiment, an appropriate solvent comprises
a
mixture of any two or more solvents, including, but not limited to, acetone,
ethanol,
nitromethane, methanol, acetonitrile, dichloromethane, water, and
tetrahydrofuran.
11
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
[0028] In another embodiment, the present invention provides a method of
making
a polymorph of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide, comprising:
(a) providing 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide Form I;
(b) contacting said 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide Form I with an appropriate solvent; and
(c) crystallizing said polymorph of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide.
[0029] In another embodiment, step (b) is completed in the presence of a
solvent
such that a solution is formed prior to crystallization of the 7-[(3-chloro-
6,11-dihydro-
6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide
polymorph. In another embodiment, step (b) is completed in the presence of a
solvent
such that a suspension is formed prior to crystallization of the 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
polymorph. In a specific embodiment, said polymorph of 7-[(3-chloro-6,11-
dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide is 7-
[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide Form II. In certain embodiments, a solvent is selected from the
group
consisting of: acetone, ethanol, nitromethane, methanol, acetonitrile,
dichloromethane,
water, and tetrahydrofuran (THF). In another embodiment, a solvent comprises a
mixture of any two or more solvents, including, but not limited to, acetone,
ethanol,
nitromethane, methanol, acetonitrile, dichloromethane, water, and
tetrahydrofuran.
[0030] The 7- [(3-chloro-6,11-dihydro-6-methyldibenzo [c, f] [1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide sodium salt can be prepared by one or more
methods known in the art, including, but not limited to, the method in US
Patent No.
3,758,528.
12
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
[0031] In one embodiment of the present invention, an amount of a polymorph of
7- [(3-chloro-6,11-dihydro-6-methyldibenzo [c,f] [1 ,2]thiazepin-11 -yl)amino]
heptanoic
acid S,S-dioxide effective to modulate a mammal's physiology and/or to treat a
mammal is administered to said mammal. In one aspect, the polymorph of 7-[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide is administered in an amount sufficient to effect modulation of a
mammal's
physiology and/or treatment.
[0032] In another embodiment, a method of treating a mammal suffering from
depression is provided, comprising administering to said mammal an effective
amount
of a polymorph of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-
11-
yl)amino]heptanoic acid S,S-dioxide. In another embodiment, a method of
treating a
mammal suffering from irritable bowel syndrome is provided, comprising
administering to said mammal an effective amount of a polymorph of 7-[(3-
chloro-
6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide. In another embodiment, a method of treating a mammal suffering from
attention deficit hyperactivity disorder is provided, comprising administering
to said
mammal an effective amount of a polymorph of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide. In
another
embodiment, a method of treating a mammal suffering from asthma is provided,
comprising administering to said mammal an effective amount of a polymorph of
7-[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide. In a specific embodiment, said polymorph is 7-[(3-chloro-6,11-
dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I. In
another specific embodiment, said polymorph is 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
II. In
another embodiment, said mammal described above is a human.
[0033] In another embodiment, the present invention includes the preparation
of a
medicament comprising a polymorph of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide. Such
a
medicament can be used for treating depression, irritable bowel syndrome,
attention
deficit hyperactivity disorder, or asthma, in a mammal in need of such
treatment. In
another embodiment, said mammal is a human.
13
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
[0034] Pharmaceutical dosage forms of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide
polymorphs
can be administered in several ways including, but not limited to, oral
administration.
Oral pharmaceutical compositions and dosage forms are exemplary dosage forms.
Optionally, the oral dosage form is a solid dosage form, such as a tablet, a
caplet, a
hard gelatin capsule, a starch capsule, a hydroxypropyl methylcellulose (HPMC)
capsule, or a soft elastic gelatin capsule. Liquid dosage forms may also be
provided by
the present invention, including such non-limiting examples as a suspension,
solution,
syrup, or emulsion.
[0035] 7- [(3-chloro-6,11-dihydro-6-methyldib enzo [c,f] [1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide polymorphs can be administered by
controlled or
delayed release means. Controlled release pharmaceutical products generally
have a
common goal of improving drug therapy over that achieved by their non-
controlled
release counterparts. Ideally, the use of an optimally designed controlled
release
preparation in medical treatment is characterized by a minimum of API (active
pharmaceutical ingredient) substance being employed to cure or control the
condition
in a minimum amount of time. Advantages of controlled release pharmaceutical
compositions generally include: 1) extended activity of the API; 2) reduced
dosage
frequency; 3) increased patient compliance; 4) usage of less total API; 5)
reduction in
local or systemic side effects; 6) minimization of API accumulation; 7)
reduction in
blood level fluctuations; 8) improvement in efficacy of treatment; 9)
reduction of
potentiation or loss of API activity; and 10) improvement in speed of control
of
diseases or conditions. (Kim, Cherng-ju, Controlled Release Dosage Form
Design, 2
Technomic Publishing, Lancaster, Pa.: 2000).
[0036] Typical daily dosage forms of the invention comprise one or more
polymorphs of 7- [(3-chloro-6,11-dihydro-6-methyldib enzo [c, f]
[1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide, in an amount of from about 10.0 mg to
about 50.0
mg, from about 12.5 mg to 37.5 mg, or from about 25.0 mg to about 37.5 mg. In
a
particular embodiment, the 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide
polymorph
for use in such a composition is Form I or Form II. The dosage amounts
described
herein are expressed in amounts of 7-[(3-chloro-6,11-dihydro-6-
14
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide in its
free
form and do not include the weight of any water or solvent molecules.
[0037] In another embodiment of the invention, a pharmaceutical composition
comprising one or more polymorphs of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide is
administered orally as needed in an amount of from about 10.0 mg to about 50.0
mg,
from about 12.5 mg to about 50.0 mg, from about 25.0 mg to about 50.0 mg, or
from
about 37.5 mg to about 50.0 mg 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide. For
example, about 12.5 mg, about 25.0 mg, or about 37.5 mg. In specific
embodiments,
pharmaceutical compositions comprising one or more polymorphs of 7-[(3-chloro-
6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide
can be administered orally in amounts of about 25.0 mg or about 37.5 mg. The
dosage
amounts can be administered in single or divided doses. In another embodiment,
a
daily dose of a pharmaceutical composition comprising one or more polymorphs
of 7-
[(3 -chloro-6,11-dihydro-6-methyldib enzo [c, f] [1,2]thiazepin-11-
yl)amino]heptanoic
acid S,S-dioxide comprises up to about 50.0 mg 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide. In
other
embodiments, the present invention is directed to compositions comprising one
or more
polymorphs of 7- [(3-chloro-6,11-dihydro-6-methyldib enzo [c, f]
[1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide as described herein and one or more
diluents,
carriers, and/or excipients suitable for the administration to a mammal for
the treatment
or prevention of one or more of the conditions described herein. In one
embodiment, a
controlled release pharmaceutical composition of one or more polymorphs of 7-
[(3-
chloro-6,11-dihydro-6-methyldibenzo [c,f] [1,2]thiazepin-11-yl)amino]heptanoic
acid
S,S-dioxide requires a less complex mixture of excipients than other
pharmaceutical
compositions comprising another form of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide.
[0038] The 7- [(3-chloro-6,11-dihydro-6-methyldib enzo [c, f] [1,2]thiazepin-
11-
yl)amino]heptanoic acid S,S-dioxide polymorphs of the present invention may
also be
used to prepare pharmaceutical dosage forms other than the oral dosage forms
described above, such as topical dosage forms, parenteral dosage forms,
transdermal
dosage forms, and mucosal dosage forms. For example, such forms include
creams,
CA 02679936 2016-09-02
lotions, solutions, suspensions, emulsions, ointments, powders, patches,
suppositories, and
the like.
[0039] The 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide polymorphic forms of the present invention
can be
characterized, e.g., by the TGA, DSC, IR spectroscopic data, or by any one,
any two, any
three, any four, any five, any six, any seven, any eight, any nine, any ten,
or any single
integer number of PXRD 2-theta angle peaks, or by any combination of the data
acquired
from the analytical techniques described herein.
[0040] In a further embodiment, there is provided 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form
I, wherein
said Form I exhibits a powder X-ray diffractogram comprising peaks at about
12.66, about
13.32, about 16.26, and about 17.64 degrees 2-theta.
[0040a] In a further embodiment, there is provided 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form I
described
herein, wherein said Form I exhibits a powder X-ray diffi-actogram further
comprising peaks
at about 12.66, about 13.32, and about 17.64 degrees 2-theta.
EXAMPLES
Example 1
743-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-
yDamino]heptanoic acid
S,S-dioxide Form I
[0041] Commercially available 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide sodium
salt (103
mg) was dissolved in water. One equivalent HC1 was added and the pH was
adjusted to 5.5
with additional HC1 (measured by pH paper). The solution turned cloudy.
Methanol was
added until the solution became clear. The solution was warmed while blowing
nitrogen gas
until it clouded. The solution was then heated until it became clear. This was
followed by
cooling the solution during sonication. Crystallization resulted and the 7-[(3-
chloro-6,11-
16
CA 02679936 2014-12-23
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yeamino]heptanoic acid S,S-
dioxide Form I
crystals were collected via centrifuge filtration.
[0042] Crystals representative of those obtained by completing the method
above were
characterized using PXRD, DSC, TGA, and IR spectroscopy. The 7-[(3-chloro-6,11-
dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)aminolheptanoic acid S,S-
dioxide Form I
crystals exhibit a PXRD diffractogram comprising peaks, for example, at about
5.89, 7.82,
8.93, 10.47, 11.22, 12.66, 13.32, 14.72, 16.26, 16.75, 17.64, 18.03, 18.75,
19.50, 20.48,
21.24, 21.56, 22.58, 23.04, 25.19, 26.54, and about 29.12 degrees
16a
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
2-theta (See Figure 1). DSC showed an endothermic transition at about 139
degrees C
(See Figure 2). TGA showed no substantial weight loss up to about 170 degrees
C (See
Figure 3). An IR spectrum of 7-[(3-chloro-6,11-dihydro-6-
methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide Form I
was
taken using a KBr pressed pellet (See Figure 4).
DIFFERENTIAL SCANNING CALORIMETRY
[0043] DSC analysis of each sample was performed using a Q1000 Differential
Scanning Calorimeter (TA Instruments, New Castle, DE, U.S.A.), which uses
Advantage for QW-Series, version 1Ø0.78, Thermal Advantage Release 2.0
(C2001
TA Instruments-Water LLC), with the following components: QDdv.exe version
1Ø0.78 build 78.2; RHBASE.DLL version 1Ø0.78 build 78.2; RHCOMM.DLL
version 1Ø0.78 build 78.0; RHDLL.DLL version 1Ø0.78 build 78.1; an TGA.DLL
version 1Ø0.78 build 78.1. In addition, the analysis software used was
Universal
Analysis 2000 for Windows 95/95/2000/NT, version 3.1E; Build 3.1Ø40 (C2001
TA
Instruments-Water LLC), or another version as specified in the drawings or
otherwise
herein.
[0044] For all of the DSC analyses, an aliquot of a sample was weighed into
either
a standard aluminum pan (Pan part # 900786.091; lid part # 900779.901) or a
hermetic
aluminum pan (Pan part # 900793.901; lid part # 900794.901 (TA Instruments,
New
Castle DE USA)). Non-solvated samples were loaded into standard pans and were
sealed either by crimping for dry samples or press fitting for wet samples
(such as
slurries). Solvated samples (including hydrates) were loaded into hermetic
pans and
hermetically sealed. The sample pan was loaded into the Q1000 Differential
Scanning
Calorimeter, which is equipped with an autosampler, and a thermogram was
obtained
by individually heating the same using the control software at a rate of 10
C/minute
from Tmin (typically 30 C) to T. (typically 300 C) using an empty aluminum pan
as a
reference. Dry nitrogen (compressed nitrogen, grade 4.8 (BOC Gases, Murray
Hill, NJ
USA)) was used as a sample purge gas and was set at a flow rate of 50
mL/minute.
Thermal transitions were viewed and analyzed using the analysis software
provided
with the instrument.
17
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
THERMOGRAVIMETRIC ANALYSIS
[0045] Thermogravimetric analysis (TGA) of samples was performed using a Q500
Thermogravimetric Analyzer (TA Instruments, New Castle, DE, U.S.A.), which
uses
Advantage for QW-Series, version 1Ø0.78, Thermal Advantage Release 2.0 (2001
TA
Instruments-Water LLC). In addition, the analysis software used was Universal
Analysis 2000 for Windows 95/98/2000/NT, version 3.1E; Build 3.1Ø40 (2001 TA
Instruments-Water LLC), or another version as specified in the drawings or
otherwise
herein.
[0046] For the TGA experiments, the purge gas used was dry nitrogen, the
balance
purge was 40 mL/minute N2, and the sample purge was 60 mL/minute N2.
[0047] TGA was performed on the sample by placing a sample of the 7-[(3-chloro-
6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide polymorph in a platinum pan. The starting temperature was typically 20
degrees C with a heating rate of 10 degrees C/minute, and the ending
temperature was
300 degrees C.
IR SPECTROSCOPY
[0048] IR spectra were obtained using NexusTM 470 FT-IR, Thermo-Nicolet, 5225
Verona Road, Madison, WI 53711-4495 and were analyzed with Control and
Analysis
software: OMNIC, Version 6.0a, (C) Thermo-Nicolet, 1995-2004. Unless otherwise
noted, all IR spectra are obtained at about room temperature (about 24 degrees
C to
about 25 degrees C).
POWDER X-RAY DIFFRACTION
[0049] Powder x-ray diffraction patters were obtained using a D/Max Rapid X-
ray
Diffractometer (Rigaku/MSC, The Woodlands, TX, U.S.A.).
[0050] The D/Max Rapid X-ray Diffractometer was equipped with a copper source
(Cu/K1.5406A), manual x-y stage, and 0.3 mm collimator. A sample was loaded
into
a 0.3 mm quartz capillary tube (Charles Supper Company, Natick, MA, U.S.A.) by
sectioning off the closed end of the tube and tapping the small, open end of
the
capillary tube into a bed of the powdered sample or into the sediment of a
slurried
sample. The loaded capillary tube was mounted in a holder that was placed and
fitted
into the x-y stage. A diffractogram was acquired using control software (RINT
Rapid
18
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
Control Software, Rigaku Rapid/XRD, version 1Ø0 (01999 Rigaku Co.)) under
ambient conditions at a power setting of 46 kV at 40 mA in transmission mode,
while
oscillating about the omega-axis from 0-5 degrees at 1 degree/second, and
spinning
about the phi-axis over 360 degrees at 2 degrees/second. The exposure time was
15
minutes unless otherwise specified.
[0051] The diffractogram obtained was integrated of 2-theta from 2-40 degrees
and
chi (1 segment) from 0-36 degrees at a step size of 0.02 degrees using the
cyllnt utility
in the RINT Rapid display software (RINT Rapid display software, version 1.18
(Rigaku/MSC)) provided by Rigaku with the instrument. The dark counts value
was
set to 8 as per the system calibration by Rigaku. No normalization or omega,
chi, or
phi offsets were used for the integration. The diffractograms included herein
show raw
data (no background subtraction).
[0052] The relative intensity of peaks in a diffractogram is not necessarily a
limitation of the PXRD pattern because peak intensity can vary from sample to
sample,
e.g., due to crystalline impurities. Further, the angles of each peak can vary
by about
+/- 0.1 degrees, or by about +/- 0.05. The entire pattern or most of the
pattern peaks
may also shift by about +/- 0.1 degrees to about +/- 0.2 degrees due to
differences in
calibration, settings, and other variations from instrument to instrument and
from
operator to operator. All reported PXRD peaks in the Figures, Examples, and
elsewhere herein are reported with an error of about 0.1 degrees 2-theta.
Unless
otherwise noted, all diffractograms are obtained at about room temperature
(about 24
degrees C to about 25 degrees C).
Example 2
7- [(3-chloro-6,11-dihydro-6-methyldibenzo [c,f] [1 ,2]thiazepin-11-yl)amino]
heptanoic
acid S,S-dioxide Form II
[0053] The resultant crystals produced from the procedure described in Example
1
were placed in methanol and heated until dissolved. Upon dissolution, a clear
solution
with a faint yellowish-brown color resulted. The solution was allowed to cool
to room
temperature. Crystals began to form. The volume was reduced via evaporation
with
nitrogen gas. 7-[(3-chloro-6,11-dihydro-6-methyldibenzo [c,f][1,2]thiazepin-11-
yl)amino]heptanoic acid S,S-dioxide Form II crystals were collected via
centrifuge
filtration.
19
CA 02679936 2009-09-02
WO 2008/109577
PCT/US2008/055746
[0054] Crystals representative of those obtained by completing the method
above
were characterized using PXRD, DSC, TGA, and IR spectroscopy. The 7-[(3-chloro-
6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-
dioxide Form II crystals exhibit a PXRD diffractogram comprising peaks, for
example,
at about 8.52, 10.46, 15.05, 16.40, 16.74, 17.14, 18.22, 20.99, 21.66, 22.68,
23.35,
23.88, 24.55, and about 26.71 degrees 2-theta (See Figure 5). DSC showed an
endothermic transition at about 148 degrees C (See Figure 6). TGA showed no
substantial weight loss up to about 150 degrees C (See Figure 7). An IR
spectrum of 7-
[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-
yl)amino]heptanoic
acid S,S-dioxide Form II was taken using a KBr pressed pellet (See Figure 8).
